Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ivacaftor. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

11 träffar

Bibliografisk träff 2012-09-01

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE, VX 08-770-104 Study Group.

Chest · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1378/chest.11-2672

Bibliografisk träff 2012-06-29

A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.

Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, Levin E, Raju SV, Li Y, Mazur M, Byan-Parker S, Grizzle W, Sorscher EJ, Dransfield MT, Rowe SM.

PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0039809

Bibliografisk träff 2012-06-26

Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.

Pettit RS.

Ann Pharmacother · review; journal article · DOI 10.1345/aph.1r076

Bibliografisk träff 2012-06-21

Personalized medicine in cystic fibrosis: dawning of a new era.

Clancy JP, Jain M.

Am J Respir Crit Care Med · journal article · DOI 10.1164/rccm.201204-0785pp

Bibliografisk träff 2012-06-12

Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.

Lubamba B, Dhooghe B, Noel S, Leal T.

Clin Biochem · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.clinbiochem.2012.05.034

Bibliografisk träff 2012-05-01

Ivacaftor, vismodegib, and ingenol mebutate.

Hussar DA, Eckel SP.

J Am Pharm Assoc (2003) · journal article · DOI 10.1331/japha.2012.12517

Bibliografisk träff 2012-04-30

Ivacaftor.

Davis PB, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov · news · DOI 10.1038/nrd3723

Bibliografisk träff 2012-04-01

Ivacaftor (Kalydeco) for cystic fibrosis.

Författaruppgift saknas

Med Lett Drugs Ther · journal article

Bibliografisk träff 2012-04-01

ACP Journal Club. Ivacaftor improved lung function in cystic fibrosis with G551D mutation.

Hadjiliadis D.

Ann Intern Med · comment; journal article · DOI 10.7326/0003-4819-156-8-201204170-02010

Bibliografisk träff 2012-01-30

Ivacaftor potentiation of multiple CFTR channels with gating mutations.

Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP, Urrutia A, Joubran J, Seepersaud S, Sussky K, Hoffman BJ, Van Goor F.

J Cyst Fibros · comparative study; journal article · DOI 10.1016/j.jcf.2011.12.005

Bibliografisk träff 2011-11-01

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS, VX08-770-102 Study Group.

N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa1105185